Yujiro Hata - Feb 8, 2024 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
President and CEO, Director
Signature
/s/ Jason Throne, as Attorney-in-Fact for Yujiro Hata
Stock symbol
IDYA
Transactions as of
Feb 8, 2024
Transactions value $
-$4,067,257
Form type
4
Date filed
2/12/2024, 04:27 PM
Previous filing
Feb 5, 2024
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $327K +75.8K +11.18% $4.31 754K Feb 8, 2024 Direct
transaction IDYA Common Stock Sale -$3.42M -75.8K -10.06% $45.15 678K Feb 8, 2024 Direct F1, F2
transaction IDYA Common Stock Options Exercise $102K +23.6K +3.48% $4.31 701K Feb 9, 2024 Direct
transaction IDYA Common Stock Sale -$1.07M -23.6K -3.36% $45.54 678K Feb 9, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (right to buy) Options Exercise $0 -75.8K -23.41% $0.00 248K Feb 8, 2024 Common Stock 75.8K $4.31 Direct F4
transaction IDYA Stock Option (right to buy) Options Exercise $0 -23.6K -9.5% $0.00 224K Feb 9, 2024 Common Stock 23.6K $4.31 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $45.00 to $45.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 This transaction was executed in multiple trades in prices ranging from $45.01 to $45.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The shares subject to the option are fully vested and exercisable.